Video

Dr. Heyman on the Use of Maintenance Rituximab in Follicular Lymphoma

Benjamin Heyman, MD, assistant clinical professor of medicine, University of California, San Diego, discusses the use of maintenance rituximab (Rituxan) in patients with follicular lymphoma.

Benjamin Heyman, MD, assistant clinical professor of medicine, University of California, San Diego, discusses the use of maintenance rituximab (Rituxan) in patients with follicular lymphoma.

The 10-year follow-up from the phase III PRIMA study demonstrated a progression-free survival advantage versus observation as well as an improvement in the time to next chemotherapy treatment. While there was no overall survival benefit with rituximab, there are a few select situations where it may be of benefit to patients, says Heyman.

For example, rituximab can be used in a patient who does not have a complete response (CR) after induction chemotherapy. These patients are at risk of early relapse, and maintenance rituximab could help get patients to a CR, says Heyman.

Rituximab maintenance can also be used in elderly patients who may not be able to tolerate another round of chemoimmunotherapy upon relapse. Patients may also prefer to be on maintenance rituximab in order to prolong their remission despite the potential for increased toxicity, concludes Heyman.

Related Videos
David Schiff, MD
Timothy Gershon, MD, PhD
Jordan Hansford, MD
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University